We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Combined With Infrared Imaging Automatically Classifies Tumors

By LabMedica International staff writers
Posted on 15 Feb 2023

In recent years, there has been a massive advancement in the available treatments for colon cancer. More...

To ensure these therapies, such as immunotherapies, are effective, it is important to accurately diagnose the individual patient to provide specifically tailored treatment. Now, researchers have paired artificial intelligence (AI) with infrared (IR) imaging to develop an automated and precise method for diagnosing colon cancer and tailoring treatments to the patient. This label-free and automated technique complements existing methods for analyzing tissue samples.

Over the course of the past several years, a research team at the Centre for Protein Diagnostics (PRODI) at Ruhr University Bochum (Bochum, Germany) has been working on creating a new digital imaging method known as label-free IR imaging. This method measures the genomic and proteomic composition of the examined tissue, providing molecular information based on the infrared spectra. The information is then decoded using AI and displayed as false-color images utilizing image analysis methods from the field of deep learning.

The PRODI team successfully demonstrated that using deep neural networks, it was possible to effectively determine the microsatellite status, a prognostically and therapeutically relevant parameter, in colon cancer. In this process, the tissue sample passes through a standardized, user-independent, automated process and allows for spatially resolved differential classification of the tumor within an hour. On the other hand, classical diagnostics is used to determine the microsatellite status either through complex immunostaining of various proteins or via DNA analysis.

The ever-improving therapy options have made fast and uncomplicated determination of such biomarkers extremely important. Based on IR microscopic data, the researchers modified, optimized, and trained neuronal networks to establish label-free diagnostics. In contrast to immunostaining, the new approach does not need dyes and is much faster than DNA analysis.

“We were able to show that the accuracy of IR imaging for determining microsatellite status comes close to the most common method used in the clinic, immunostaining,” said PhD student Stephanie Schörner.

Related Links:
Ruhr University Bochum 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
Repetitive Pipette
VWR® Stepper Pro
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.